门冬氨酸钾镁联合胺碘酮治疗室性心律失常的疗效评价

Clinical effect appraisal of potassium magnesium aspartate and amiodarrone for injection treats coronary disease ventricular arrythmia

目的观察门冬氨酸钾镁联合胺碘酮治疗冠心病患者室性心律失常(VA)的疗效。方法将62例冠心病伴VA患者随机分为治疗组32例和对照组30例。2组均给予常规治疗,治疗组加用门冬氨酸钾镁联合胺碘酮,对照组单用胺碘酮。使用ESVEM标准评定2组的疗效。结果治疗组总有效率为93.8%高于对照组的73.3%,差异有统计学意义(P<0.05)。2组用药前后心电图PR间期、QRS时限比较,差异无统计学意义(P>0.05),且均未见明显不良反应。结论门冬氨酸钾镁联合胺碘酮治疗VA患者效果显著,不良反应少,安全可靠,值得临床应用。

Objective To observe potassium magnesium aspartate and amiodarrone for injection treats coronary disease patient with ventriculararrythmia （VA） curative effect. Methods 62 example VA patients were randomly divided into 2 groups：the treatment group of 32 examples, was given conventional treatment, potassium magnesium aspartate and amiodarrone for injection ;The control group of 30 examples ,was given conventional treatment ＋ aspartate and amiodarrone hrdrochloride for Injection. Used the ESVEM standard to evaluate VA the curative effect. Results The treatment group total effectiveness was 93.8% ,and the control group total effectiveness was 73.3% ,the difference had statistics significance（P 〈 0.05 ）. Around the two groups of medications electrocardiogram PR time, QRS time limit comparison, difference non-statistics significance （ P 〉 0. 05）. The two groups even had not seen the obvious untoward effect. Conclusion The observation potassium magnesium aspartate and amiodarrone for injection treats VA the patient effect to be remarkable, the untoward effect are few, safe reliable,is worth the clinical practice.